Tango Therapeutics (TNGX) Net Income towards Common Stockholders (QoQ) (2020 - 2026)

Tango Therapeutics (TNGX) Net Income towards Common Stockholders (QoQ) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Tango Therapeutics 3.86 Bn 3.70 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -17.46%
Dec 31, 2025 -343.94%
Sep 30, 2025 140.88%
Jun 30, 2025 2.57%
Mar 31, 2025 -5.86%
Dec 31, 2024 -29.15%
Sep 30, 2024 -14.15%
Jun 30, 2024 32.61%
Mar 31, 2024 -23.38%
Dec 31, 2023 -38.03%
Sep 30, 2023 -7.31%
Jun 30, 2023 25.93%
Mar 31, 2023 3.77%
Dec 31, 2022 -0.19%
Sep 30, 2022 -16.86%
Jun 30, 2022 1.39%
Mar 31, 2022 -14.34%
Dec 31, 2021 -12.54%
Sep 30, 2021 -336.01%
Jun 30, 2021 62.89%